Vaxcyte News and Activities
Presence
Vaxcyte develops vaccines for bacterial infectious diseases. Its main products are vaccine candidates and research services for healthcare providers, public health programs, and patients who need better disease prevention.
Vaxcyte products and services overview:
- Vaccine candidates
- Pneumococcal vaccines
- Shingles vaccines
- Research services
Revenue: ~$0 million
Employees: 300
Headquarters: San Carlos, United States (USA)
Vaxcyte is one of the...
Vaxcyte is a company listed under the stock ticker PCVX (US).
Executives
View the org chart displaying its 45 main executives
Most searched biographies at Vaxcyte
- Grant Pickering, President, Chief Executive Officer and Director
- Jacks Lee, Director
- Annie Drapeau, Director
Popular executive movements at Vaxcyte
- Robert Paris has joined the company as Senior Vice President of Clinical Development (posted on June 30 2026).
- Moncef Slaoui has joined the company as Director (posted on June 24 2026).
- Jacks Lee, Director, has left the company (posted on June 24 2026).
Click here to view some more movements at Vaxcyte
Create your alert
to follow the executive moves at Vaxcyte.
Biotechnology
Vaxcyte has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by Vaxcyte
- Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - Vaxcyte, Inc.
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Vaxcyte, Inc.
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Vaxcyte, Inc.
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - Vaxcyte, Inc.
- Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Vaxcyte, Inc.
- Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - Vaxcyte, Inc.
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Vaxcyte, Inc.
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - Vaxcyte, Inc.
- View more press releases Close
Social media about Vaxcyte
- Vaxcyte on Wikipedia, Google News & Yahoo Finance
- Vaxcyte on LinkedIn, X (Twitter) & YouTube
